All Topics
All Topics
Technology
Technology
AI
AI
Business
Business
Entertainment
Entertainment
News
News
Programming
Programming
Science
Science
Design
Design
Environment
Environment
Finance
Finance
Crypto
Crypto
Politics
Politics
Sports
Sports
Education
Education
Gaming
Gaming
Art
Art
Music
Music
Health
Health
Security
Security
Books
Books
Food
Food
Travel
Travel
Personal
Personal
Bluesky
Twitter

Health Canada-approved cancer drug lifileucel remains inaccessible to patients awaiting provincial funding decisions

A 37-year-old Ontario father with metastatic melanoma, Alex Shved, is unable to access TIL therapy (lifileucel) — a personalized cancer treatment approved by Health Canada in August 2024 — because it is still under review for public funding by provincial health systems. The article highlights the gap between federal drug approval and provincial funding decisions, which leaves patients in limbo and unable to access potentially life-saving treatments.

Kelly Grant9d ago7 min readenNews
Read on theglobeandmail.com

Key quotes

Alex Shved has been e-mailing Ontario politicians and filing appeals at the speed of a man who knows he doesn't have time to waste.
Despite Health Canada having approved a commercial version of TIL therapy called lifileucel last August, Mr. Shved can't get it.
Ontario parents hope son's death can change Canada's approach to novel cancer treatments.

From the article

A bespoke treatment for metastatic melanoma is unavailable to Canadians because it is still being reviewed for public funding
Continue reading on theglobeandmail.com

You might also wanna read

Comments

Sign in to join the conversation.

No comments yet. Be the first.